leadf
logo-loader
viewAequus Pharmaceuticals Inc.

Aequus Pharmaceuticals poised for increased growth with new life changing products

Aequus Pharmaceuticals (CVE:AQS) CEO Doug Janzen joined Steve Darling in the Vancouver Proactive studio to give details about his company. Those detail include drugs already at market and others in the pipeline.

Janzen also shared information on one of those drugs, Aequus 1303 which is being developed to help pregnant women with nausea. Janzen also talked about their revenue streams and future outlook for the company. 

Quick facts: Aequus Pharmaceuticals Inc.

Price: 0.215 CAD

TSX-V:AQS
Market: TSX-V
Market Cap: $24.06 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Aequus Pharmaceuticals receives approval for Evolve Gel lubricating eye...

Aequus Pharmaceuticals (CVE: AQS- OTCQB: AQSZF) CEO Doug Janzen joined Steve Darling from Proactive Vancouver with news the company has been granted a medical device licence for Evolve Intensive Gel. This product is a preservative free treatment for moderate to severe forms of dry-eye...

on 19/10/20

2 min read